Development of a stable liquid formulation of live attenuated influenza vaccine

White, Jessica A.; Estrada, Marcus; Flood, E. Alexander; Mahmood, Kutub; Dhere, Rajeev; Chen, Dexiang

doi:10.1016/j.vaccine.2016.04.074

Cited by 12 publications

(9 citation statements)

References 43 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only a small number of formulations for liquid phage product have been published, which is probably due to the stability issues of these methods (Ahiwale et al, 2013;. Inspiration to design liquid formulations for phage might be found in liquid formulations for live virus vaccines for aquaculture, such as White's et al contribution to the subject (White et al, 2016).…”

Section: Stabilizing and Delivering Phages Thanks To Galenicsmentioning

confidence: 99%

Overcoming the challenges of phage therapy for industrial aquaculture: A review

2019

View full text Add to dashboard Cite

Aquaculture is the fastest-growing sector in food industry. Its development is powered by the intensification of the production which increased bacterial disease occurrence and spreading. As aquaculture deeply relies on a massive prophylactic and therapeutic use of antibiotics, it is threatened by the emergence of multi drug resistant bacteria. The stalled development of new antibiotics makes finding new therapeutic solutions a burning issue. Thanks to their specific host range, their ability to treat both the farmed species and the environment, their limited ecological impact and their abundance in the environment, bacteriophages represent a promising sustainable solution to control pathogenic aquaculture bacteria. In this review we discuss the interest of phage biocontrol for aquaculture and how can bacterial resistance, ecological, pharmacological and production related issues be solved.

show abstract

Section: Stabilizing and Delivering Phages Thanks To Galenicsmentioning

confidence: 99%

Overcoming the challenges of phage therapy for industrial aquaculture: A review

2019

View full text Add to dashboard Cite

show abstract

“…However, it was found that between 0.3 and 1.0 M osmolytes have the ability to cause virus flocculation . Yet, the flocculation system does not change the infectivity of the virus, which was the measure of stability for the influenza virus study, therefore the study of influenza virus stability and this work are not necessarily contradictory to one another.…”

Section: Discussionmentioning

confidence: 92%

“…It has also been determined that osmolytes can stabilize proteins and are often used in protein formulations . Influenza virus formulations can also be stabilized with concentrations of osmolytes around 0.5 M . However, it was found that between 0.3 and 1.0 M osmolytes have the ability to cause virus flocculation .…”

Section: Discussionmentioning

confidence: 99%

“…36 It has also been determined that osmolytes can stabilize proteins and are often used in protein formulations. 16 Influenza virus formulations can also be stabilized with concentrations of osmolytes around 0.5 M. 37 However, it was found that between 0.3 and 1.0 M osmolytes have the ability to cause virus flocculation. 22,23 Yet, the flocculation system does not change the infectivity of the virus, which was the measure of stability for the influenza virus study, 37 therefore the study of influenza virus stability and this work are not necessarily contradictory to one another.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A generalized purification step for viral particles using mannitol flocculation

Heldt

Saksule

Joshi

et al. 2018

Biotechnology Progress

View full text Add to dashboard Cite

Vaccine manufacturing has conventionally been performed by the developed world using traditional unit operations like filtration and chromatography. There is currently a shift in the manufacturing of vaccines to the less developed world, requiring unit operations that reduce costs, increase recovery, and are amenable to continuous manufacturing. This work demonstrates that mannitol can be used as a flocculant for an enveloped and nonenveloped virus and can purify the virus from protein contaminants after microfiltration. The recovery of the virus ranges from 58 to 96% depending on virus, the filter pore size, and the starting concentration of the virus. Protein removal of 80% was achieved for the small nonenveloped virus using a 0.1 µm filter because proteins were not flocculated with the virus and flowed through the filter. It is hypothesized that mannitol dehydrates the viral surface by controlling the water structure surrounding the virus. Without the ability to become compact, as occurs with proteins, the virus aggregates in the presence of osmolytes and proteins do not. Osmolyte flocculation is a scalable process using high flux microfilters. It has been applied to both an enveloped and nonenveloped virus, making this process friendly to a variety of vaccine and gene therapy products. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 34:1027-1035, 2018.

show abstract

“…In addition, the need of a cold-chain during distribution and storage is expensive and difficult to guarantee especially in developing countries (Soema et al, 2015). Therefore, development of tools aiming at improving antigen stability and driving freeze-drying manufacturing processes by including excipients to the formulation would greatly improve the shelf life, transport and storage duration of influenza vaccines (Geeraedts et al, 2010;Soema et al, 2014;White et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Roads to advanced vaccines: influenza case study

Riese

Guzmán

2017

Microbial Biotechnology

View full text Add to dashboard Cite

SummaryVaccines represent a cornerstone to ensure healthy lives and promote well‐being for all at all ages. However, there are many diseases for which vaccines are not available, are relatively ineffective or need to be adapted periodically. Advances in microbial biotechnology will contribute to overcoming these roadblocks by laying the groundwork for improving and creating new approaches for developing better vaccines, as illustrated here in the case of influenza.

show abstract

Development of a stable liquid formulation of live attenuated influenza vaccine

Abstract: HighlightsMultiple excipients were screened for their ability to stabilize influenza vaccine.Identified a liquid formulation with storage stability for one year at 2–8 °C.A stable liquid formulation may lead to wider use of influenza vaccination.

Cited by 12 publications

References 43 publications

Overcoming the challenges of phage therapy for industrial aquaculture: A review

Overcoming the challenges of phage therapy for industrial aquaculture: A review

A generalized purification step for viral particles using mannitol flocculation

Roads to advanced vaccines: influenza case study

Contact Info

Product

Resources

About